Johnson & Johnson posts mixed quarterly results, suspends vaccine forecast

Johnson & Johnson posts mixed quarterly results, suspends vaccine forecast
Published - Apr 20, 2022 @ 3:51 PM (EET)


For the first quarter of 2022, healthcare behemoth Johnson & Johnson (NYSE:JNJ) posted mixed results, having surpassed earnings but missed revenue expectations.


Driven primarily by a 6.3% and 5.9% year-over-year increase in the Pharmaceutical and MedTech segments, quarterly revenues stood at $23.4 billion, up 5% from the same quarter last year.

Spurred by growth in contact lenses and artificial-knee replacements, revenues from J&J's medical-device unit were $6.97 billion. Pharmaceutical revenues of $12.87 billion were driven by treatments for several immune-mediated inflammatory diseases.


However, the figure failed to meet estimates of $23.67 billion. Adjusted earnings per share (EPS) rose 3.1% to $2.67, above Wall Street estimates of $2.58.


Additionally, Johnson & Johnson cut its full-year guidance of $95.9 billion to $96.9 billion from a previous projection and now expects revenue of $94.8 billion to $95.8 billion.


J&J expects earnings for 2022 to be in the range of $10.15-$10.35 per share against the consensus estimate pegged at $10.52 per share.


Looking ahead, CEO Joaquin Duato remains confident in the future of Johnson & Johnson as they "continue advancing their portfolio and innovative pipeline."


COVID-19 VACCINE


As uncertainty looms over how the pandemic will affect demand, Johnson & Johnson suspended its full-year sales forecast for its Covid-19 vaccine.


In its most recent quarter, the healthcare-products company said that Covid-19 shots helped lift over sales, having sold $457 million of the vaccines. Shortly after the vaccine shot received authorization in the U.S., in the same period last year, the company's vaccine sales were $100 million.


Vaccine matters aside, Chief Financial Officer Joseph Wolk said the new guidance reflects an expectation that negative currency-exchange trends could reduce full-year sales by $2.5 billion and cut adjusted earnings by 45 cents a share.


STOCK RATING


Wall Street analysts are cautiously optimistic about the stock based on six Buys and five holds and have a Moderate Buy Consensus rating.  


The stock's average price target of $190.09 implies an upside potential of 3.8% from current levels. Over the past year, shares of the company have grown 9.9%.

PRICE TARGET:  In Tuesday's extended trading session, shares rose almost 3.5% to close at $183.78.



Live News

Market Movers

By clicking “Accept All Cookies”, you agree to the storing of cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts. View our Privacy Policy for more information.